Evidence map›Paper›PMID 38675561›Full record

ArticleMolecules (Basel, Switzerland)2024

Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling.

Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, Michele Tonelli, Evgeny Kanov, Anna Carbone, Paola Fossa, Raul R Gainetdinov, Elena Cichero, Silvia Schenone

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Giancarlo GrossiDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.
Naomi ScaranoDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.ORCID 0000-0002-5121-715X
Francesca MusumeciDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.ORCID 0000-0002-7228-0086
Michele TonelliDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.ORCID 0000-0003-1518-2890
Evgeny KanovInstitute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Anna CarboneDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.ORCID 0000-0002-6767-2376
Paola FossaDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.ORCID 0000-0001-9386-0445
Raul R GainetdinovInstitute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia.
Elena CicheroDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.
Silvia SchenoneDepartment of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genoa, Viale Benedetto XV, 3, 16132 Genoa, Italy.
University of Genoa · ITSt Petersburg University · RU

Funding

Russian Science Foundation 19-75-30008-PUniversity of Genoa FRA2022
6 · The paper itself

Abstract

The search for novel effective TAAR1 ligands continues to draw great attention due to the wide range of pharmacological applications related to TAAR1 targeting. Herein, molecular docking studies of known TAAR1 ligands, characterized by an oxazoline core, have been performed in order to identify novel promising chemo-types for the discovery of more active TAAR1 agonists. In particular, the oxazoline-based compound

Indexed as

Molecular Docking SimulationReceptors, G-Protein-CoupledBenzimidazolesBinding SitesDrug DiscoveryHumansLigandsModels, MolecularMolecular StructureOxazolesProtein BindingStructure-Activity RelationshipTrace Amine-Associated ReceptorsBenzimidazolesLigandsOxazolesReceptors, G-Protein-CoupledTrace Amine-Associated ReceptorsagonistAlphaFoldmolecular dockingTAAR1trace amine receptor

Identifiers

PMID38675561
PMCPMC11052455
OpenAlexW4394761291

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.